Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis
Tao Jiang(Tongji University), Caicun Zhou(Tongji University), Fei Zhou(Shanghai University), Shengxiang Ren(Tongji University), Yan Wang(Liaoning Academy of Agricultural Sciences), Guanghui Gao(Tongji University)
Cited by 66
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504